In-vitro tumor cell treatment method, treated cell and application of treated cell in preparation of autologous tumor vaccine
Through ex vivo tumor cell treatment and lethal dose radiation technology, autologous tumor vaccines were prepared, which solved the problem of insufficient therapeutic efficacy of existing tumor vaccines, achieved individualized tumor treatment, significantly inhibited tumor growth and had the characteristics of economical and efficient.
Patent Information
- Application Number
- CN202411098987.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-08-12
AI Technical Summary
The therapeutic efficacy of existing tumor vaccines is insufficient, especially due to the difficulty in selecting mRNA nucleotide sequences and the high cost and insufficient accuracy of individualized neoantigens prediction, resulting in poor therapeutic efficacy of tumor vaccines.
Ex vivo tumor cell treatment method, through in vitro culture and given a lethal dose of radiation, the tumor cells enter an immunogenic death state, release tumor-related antigens, and are used to prepare autologous tumor vaccines and activate the patient's immune system to carry out primary tumors. Targeted attacks.
An individualized tumor vaccine can significantly inhibit tumor growth and prevent recurrence, and has the advantages of simple production, low cost, fast production and accurate efficacy.
Smart Images

Figure CN118879633A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the fields of medicine and oncology, and in particular to an in vitro tumor cell processing method, cells obtained after the processing, and application of the cells in preparing autologous tumor vaccines. Background Art
[0002] Different from preventive vaccines for infectious diseases, most of the tumor vaccines currently being explored are therapeutic vaccines, and the main technical route is mRNA (messenger RNA) vaccine. The principle is: mRNA encapsulated in liposomes and translated into tumor-associated antigens is injected into the systemic circulation. With the assistance of liposomes, mRNA enters human cells, is translated into tumor-associated antigens in cells, and is recognized by antigen-presenting cells through the presentation of MHC molecules. Subsequently, the body's cellular immunity and / or humoral immune system are activated, breaking the immune tolerance established by the primary tumor in the body, prompting the immune system to produce an immune response to the tumor to achieve the purpose of treatment. In this technical route, the selection of mRNA nucleotide sequence is the key, and the specific tumor-associated antigen to be used as the immunogen is still undecided, and the prediction of individualized new antigens through existing sequencing technology has the problems of high cost and insufficient accuracy, which ultimately leads to unsatisfactory therapeutic efficacy of mRNA tumor vaccines.
[0003] Another technical approach is to make vaccines based on tumor cells themselves. Some teams have repeatedly frozen and thawed certain stable tumor cell lines to try to obtain tumor antigens in tumor cells, and then mixed the lysate with immune adjuvants to make vaccines, but this technical approach has not yet published any positive results in clinical or animal models. Summary of the invention
[0004] In response to the difficulties in tumor vaccine research in the prior art, the present invention provides a new method for processing tumor cells in vitro. The obtained treated tumor cells can be used to prepare autologous tumor vaccines. Individualized tumor antigens are used to more specifically train the antigen-presenting cells in the patient's body to recognize the patient's own primary tumor, effectively inhibit tumor growth, and provide a new idea for tumor treatment.
[0005] The technical solution of the present invention is described in detail as follows: In a first aspect, the present invention provides an ex vivo tumor cell treatment method, the treatment method comprising: amplifying the separated patient's own tumor cells by in vitro culturing, and then irradiating them with a lethal dose.
[0006] The lethality mentioned above refers to the destruction of the DNA structure in the living tumor cells to achieve immunogenic death. Irradiation using ionizing radiation or any other radiation that can destroy the DNA structure in the cells is applicable to the present invention. Studies have found that tumor cells will enter a process of immunogenic death after being irradiated with ionizing radiation. In this process, tumor cells will release adjuvant-like molecules, break the membrane and release tumor-associated antigens, attracting effector T cells in the body's immune system to enter the tumor microenvironment.
[0007] The in vitro culture expansion includes, but is not limited to, various in vitro culture expansion methods such as primary cell culture, serial cell culture, 2D culture, 3D culture, and organoid culture.
[0008] Optionally or preferably, the separated patient's own tumor cells are derived from a tumor tissue sample obtained from the patient by biopsy or surgery.
[0009] Optionally or preferably, the irradiation is ionizing radiation.
[0010] Optionally or preferably, the ionizing radiation is X-rays, gamma rays or any other radiation type that can destroy the DNA structure in cells. These high-energy rays are conducive to completely destroying all DNA of tumor cells in a short period of time, causing them to enter an irreversible death program.
[0011] Optionally or preferably, the ionizing radiation time is within 6 hours. More preferably, it is within 2 hours. The purpose of shortening the irradiation time is, on the one hand, to cause as few tumor cells as possible to die due to environmental changes (rather than irradiation), because cell death caused by environmental changes is not necessarily immunogenic; on the other hand, shortening the irradiation time allows tumor cells that have died immunogenic to be injected into the tumor microenvironment as early as possible, so that the process of releasing tumor-associated antigens occurs as much as possible in the tumor microenvironment.
[0012] Optionally or preferably, the dose of the ionizing radiation is above 100 Gy.
[0013] Optionally or preferably, the dose of the ionizing radiation is 1000Gy~5000Gy.
[0014] In a second aspect, the present invention provides a treated tumor cell obtained by any of the above methods.
[0015] In a third aspect, the present invention provides the use of the above-treated tumor cells in the preparation of tumor vaccines.
[0016] After the treatment, the tumor cells are made into autologous tumor vaccines, and the vaccine is quickly injected into the primary tumor of the same patient, which can cause a large number of artificially amplified autologous tumor cells to undergo immunogenic death in the original tumor microenvironment. In this process, the coexistence of antigens and adjuvants will activate the body's cellular immune system, and a large number of effector T cells will enter the tumor microenvironment and launch a fatal attack on the primary tumor, causing the tumor to regress, thereby playing a role in treating tumors and preventing recurrence. Because the tumor antigens in the vaccine come from the patients who are to receive the vaccine treatment, it is a personalized tumor vaccine.
[0017] In a fourth aspect, the present invention provides an autologous tumor vaccine comprising the above-treated tumor cells.
[0018] Optionally or preferably, the autologous tumor vaccine further comprises an immune adjuvant or an immune activator.
[0019] In a fifth aspect, the present invention provides a method for preparing any of the above autologous tumor vaccines, comprising the following steps: (1) Obtain tumor tissue blocks from patients, clean, wash, and chop them, add digestive enzymes to digest them, obtain single tumor cells, wash and remove the digestive enzymes, add cell culture medium, and perform primary culture of tumor cells; (2) Primary culture of tumor cells to the logarithmic growth phase, and then subculture and expand the tumor cells; (3) irradiating the expanded tumor cells with a lethal dose; (4) Adjust the concentration of irradiated tumor cells to produce an autologous tumor vaccine.
[0020] Irradiated tumor cells can also be mixed with immune adjuvants to make autologous tumor vaccines. After the autologous tumor vaccine is prepared, it should be injected as soon as possible.
[0021] The concentration of irradiated tumor cells in the vaccine can be estimated based on the patient's primary tumor load. To ensure the therapeutic effect of the vaccine, if the patient's primary tumor is large, a larger number of tumor cells are required for vaccine production. Generally, the number of tumor cells required to produce a single dose of tumor vaccine is at least 10 6 indivual.
[0022] The autologous tumor vaccine of the present invention must be prepared and used immediately, and can be used by intratumoral injection (for solid tumors) or intravenous injection (for blood tumors).
[0023] Compared with the prior art, the present invention has the following beneficial effects: The present invention obtains tumor cells from the patient's primary tumor, which are used to produce tumor antigens required for the vaccine after irradiation. The vaccine is a personalized tumor vaccine, one vaccine for one person, and more targeted. The tumor antigens in the vaccine are released by tumor cells after being irradiated with a lethal dose. After irradiation, all tumor cell DNA is completely destroyed, all lose their ability to proliferate and enter the immunogenic death program, and release a large number of tumor-related antigens during the death process. The antigens released by the autologous tumor cells after being irradiated with a lethal dose after entering the original patient's body can more specifically train the body's antigen-presenting cells to recognize existing primary tumors, and then promote the activated killer T cells to infiltrate into the tumor microenvironment, accurately kill the tumor, and thus achieve a significant tumor treatment effect.
[0024] Compared with the mainstream technical route of existing tumor vaccines, the autologous tumor vaccine of the present invention has the advantages of simple preparation, low cost, rapid production and definite efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 This is a schematic diagram of the process of the in vitro tumor cell treatment method in Example 1.
[0026] Figure 2 This is a graph showing the results of Example 2, which shows that ionizing radiation can cause immunogenic death of tumor cells.
[0027] Figure 3 This is the result of Example 3 showing the inhibition of mouse tumor growth by the vaccine: comparison of different treatments for mice in the control group and experimental group and the tumor volume growth curves after subcutaneous tumor formation.
[0028] Figure 4 The figure shows the volume of subcutaneous tumors of mice in the control group and the experimental group before and after complete sampling after 11 days of growth in Example 3, and compares the results of weighing the tumors of the two groups after sampling.
[0029] Figure 5 The results of immunohistochemical CD8 staining of the tumor microenvironment in the control group and the experimental group in Example 3 are shown, and the CD8 + Comparison of T cell density. DETAILED DESCRIPTION
[0030] In order to enable those skilled in the art to better understand the present application, the present application will be described clearly and completely in conjunction with the embodiments and drawings. Obviously, the described embodiments are only embodiments of a part of the present application, not all embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in the field without creative work should fall within the scope of protection of the present application. The biological materials, instruments, and reagents used in the embodiments are all derived from commercial channels unless otherwise specified.
[0031] Example 1 Tumor vaccine preparation Please refer to Figure 1 , is a flow chart for the preparation of tumor vaccines, the preparation process is as follows: Step 1: Obtain a small amount of tumor tissue from a patient who is to receive tumor vaccine treatment through surgery or biopsy; generally, a tumor tissue block the size of a mung bean is sufficient, and there is no limit to the amount of tumor tissue.
[0032] Step 2: Primary culture of the obtained tumor tissue. The operation process mainly includes: removing fat, connective tissue and necrotic parts from the obtained tumor tissue, washing it three times with Hank's solution in a plate, chopping the tissue into 1-2 mm 3 Cut the chopped tissue into small pieces, add 2000U / ml collagenase, digest at 37℃ for at least 30min to make it into a single cell suspension, remove the digestion solution and add cell culture medium for culture. During the primary cell culture, gradient centrifugation can be used to remove lymphocytes mixed in tumor cells, and repeated adhesion method can be used to remove fibroblasts mixed in tumor cells.
[0033] Step 3: When the tumor cells cultured in step 2 enter a stable and rapid growth phase, the tumor cells are passaged and expanded as needed. Usually, in a single tumor vaccine treatment, the number of tumor cells required for vaccine production is at least 10 6 In addition, the final required amount can also be estimated based on the patient's own primary tumor load. To ensure the therapeutic effect of the vaccine, if the patient's primary tumor is large, the amount of tumor cells required to make the vaccine is larger. Unused tumor cells can be frozen for subsequent use by the same patient; in addition, cryopreservation can be performed specifically for a purpose.
[0034] Step 4: Resuspend the expanded tumor cells in Opti-MEM™ Reduced Serum Medium (PBS or saline) and transfer an appropriate amount of tumor cells to a 1.5 ml EP tube after counting.
[0035] Step 5: Place the EP tube containing tumor cells in the irradiation equipment and irradiate with a lethal dose, which must be at least 100 Gy, usually 1000-5000 Gy. The dose rate output by the irradiation equipment should be adjusted so that the irradiation process is completed within 6 hours (preferably 2 hours).
[0036] Step 6, taking out the irradiated tumor cells from the irradiation device.
[0037] Step 7: Mix an appropriate amount of immune adjuvant with the irradiated tumor cells to prepare a vaccine. The vaccine must be prepared before use.
[0038] Example 2 Ionizing radiation can cause immunogenic death of tumor cells Please refer to Figure 2 In Figure A, mice bearing MC38 tumor cells were subcutaneously inoculated and divided into two groups. The experimental group was irradiated with 5×2Gy local tumor X-rays, while the control group was not irradiated. Six days after the irradiation, the samples were taken and photographed. The results showed that the tumor volume of the experimental group mice was smaller than that of the control group to varying degrees. Figure 2 As shown in B.
[0039] RNA was extracted from tumor tissues of mice in the experimental and control groups to detect the transcription levels of death-related genes. The results are as follows: Figure 2 As shown in Figure C, the transcription levels of genes related to the pan-apoptosis pathway were generally upregulated in the tumor tissues of the experimental group mice. CD8 immunohistochemical staining was performed on the tumor tissues of the experimental and control group mice. Figure 2 As shown in D, CD8 + The density of T cells (effector T cells) was significantly higher than that in the control group. Figure 2 E in the middle is CD8 + Statistical comparison of the number of T cells showed that CD8 + The number of T cells (effector T cells) was significantly increased compared with the control group (p < 0.01, t test).
[0040] Experiments have shown that tumor cells undergo immunogenic death after X-ray irradiation.
[0041] Example 3 Animal Experiment on the Therapeutic Effect of Tumor Vaccine Balb / c female mice aged 6-8 weeks were used as experimental subjects and divided into an experimental group and a control group, with 7 mice in each group, and were treated as follows: Control group: CT26 tumor cells were injected subcutaneously, and the inoculation amount of CT26 tumor cells was 5×10 5 ( / 100 μL PBS); Experimental group: subcutaneous injection of CT26 tumor cells, the inoculation amount of CT26 tumor cells was 5×10 5 On this basis, the tumor cells inoculated into each mouse in the experimental group were mixed with the tumor vaccine of the present invention, and the tumor vaccine received by each mouse contained 1.25×10 5 Irradiated CT26 tumor cells and immune adjuvants.
[0042] The two groups of mice were kept under the same conditions, and the vernier caliper method was used to evaluate the tumor growth. After 11 days of subcutaneous tumor growth, the mouse tumor was completely sampled and photographed before sampling. The tumor was photographed and weighed after sampling, and the tumor tissues of all mice were subjected to immunohistochemical CD8 staining.
[0043] The experimental results are as follows Figure 3-5 shown. Figure 3 A shows the treatment methods of the two groups of mice, and B shows the statistical comparison of subcutaneous tumor growth in the two groups of mice. Figure 3 B shows that compared with the control group, the tumor vaccine significantly inhibited the tumor growth rate of the experimental group mice, indicating that the tumor vaccine has a significant inhibitory effect on the growth of subcutaneous tumors in mice.
[0044] Figure 4 A in the middle is a photo of a mouse before complete sampling after the subcutaneous tumor had grown for 11 days. As can be seen from the figure, the volume of the subcutaneous tumor in the experimental group of mice is generally smaller. Figure 4 B is a photo of the tumor after complete sampling. It can be clearly seen that the tumor volume of the mice in the experimental group is generally smaller. Figure 4 C is the result of weighing and comparing the tumors of all mice one by one after sampling. The statistical results show that the tumor weight of mice in the experimental group is significantly smaller than that in the control group (p<0.001, t test).
[0045] Figure 5 The results of immunohistochemical CD8 staining of tumor tissues show that CD8 + The density of T cells (effector T cells) was significantly higher than that of the control group, which confirmed that the tumor vaccine can induce the body's effector T cells to infiltrate into the tumor and kill tumor cells, thereby inhibiting tumor growth. As shown in Figure A, representative images of immunohistochemical CD8 staining of tumor tissues of mice in the control group (left) and the experimental group (right), with more CD8 staining in the experimental group; Figure B, CD8 in tumor tissues of mice in the experimental group + The density of T cells (effector T cells) was significantly greater than that of the control group (p<0.001, t test).
[0046] By injecting autologous tumor vaccines, the body's immune system can be effectively activated, prompting it to accurately kill primary tumors in the body. The use of autologous tumor vaccines can protect the body's normal cells to the greatest extent and focus on killing tumor cells, providing a new direction for personalized tumor treatment.
[0047] The invention concept is described in detail using specific examples herein, and the description of the above embodiments is only used to help understand the core idea of the invention. It should be pointed out that any obvious modification, equivalent substitution or other improvement made by a person of ordinary skill in the art without departing from the invention concept should be included in the protection scope of the present invention.
Claims
1. A method for treating tumor cells in vitro, It is characterized in that The treatment method comprises: amplifying the separated patient's own tumor cells by in vitro culture, and then irradiating them with a lethal dose.
2. The method according to claim 1, It is characterized in that The separated patient's own tumor cells are derived from tumor tissue samples obtained from the patient through biopsy or surgery.
3. The method according to claim 1, It is characterized in that The irradiation is ionizing radiation.
4. The method according to claim 3, It is characterized in that The duration of the ionizing radiation is within 6 hours.
5. The method according to claim 3, It is characterized in that The dose of the ionizing radiation is 1000 Gy~5000 Gy.
6. A treated tumor cell, It is characterized in that Obtained by the method according to any one of claims 1 to 5.
7. Use of the treated tumor cells according to claim 6 in preparing tumor vaccines.
8. An autologous tumor vaccine, It is characterized in that Containing the treated tumor cells according to claim 7.
9. The autologous tumor vaccine according to claim 8, It is characterized in that It also contains immune adjuvants or immune activators.
10. The method for preparing the autologous tumor vaccine according to claim 8 or 9, It is characterized in that The following steps are involved: (1) Obtain tumor tissue blocks from patients, clean, wash, and chop them, add digestive enzymes to digest them, obtain single tumor cells, wash and remove the digestive enzymes, add cell culture medium, and perform primary culture of tumor cells; (2) Primary culture of tumor cells to the logarithmic growth phase, and then subculture and expand the tumor cells; (3) irradiating the expanded tumor cells with a lethal dose; (4) Adjust the concentration of irradiated tumor cells to produce a tumor vaccine.
Citation Information
Patent Citations
Tumor vaccine and preparation method thereof
CN103446580A
Preparation method and application of autologous tumor vaccine
CN103800896A
Tumor cell vaccine and preparing method thereof
CN103920145A
Autologous tumor vaccines and methods
CN105873639A
Tumor vaccine composition, and preparation method and application thereof
CN111375054A
Cited By
Life body restoration based on jade law rule-prepared sulfide lattice resonance annihilation
CN122519998A
